RQ Bio is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging and new viral infections.
Location: United Kingdom, England, London
Employees: 1-10
Total raised: $115M
Investors 2
| Date | Name | Website |
| 23.12.2024 | Oxford Uni... | innovation... |
| - | Life Arc V... | lifearcven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.06.2026 | Series A | $115M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.06.2026 | EQT Life Sciences participates in RQ Bio’s USD 115 million Series A financing | EQT Life Sciences participates in RQ Bio’s USD 115 million Series A financing Wed, Jun 24, 2026 09:15 CET Report this content EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongsi... |
| 24.06.2026 | RQ Bio Raises £85.5M in Series A Funding | RQ Bio, a London, UK-based biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations, raised £85.5M in Series A funding. The round was led by Frazier Li... |
| 03.04.2024 | Clare Terlouw, Head of LifeArc Ventures, talks about the LifeArc co-founded company RQ Bio licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-... | - |
| 03.04.2024 | Kovilen Sawmynaden, Senior Principal Scientist at LifeArc, explains the science behind RQ Bio’s monoclonal antibodies against SARS-CoV-2 – | - |
| 18.03.2024 | RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19 | RQ Biotechnology Ltd. (“RQ”) a leader in the discovery of antibodies for the treatment of infectious disease, today announced that the UK Intellectual Property Office (IPO) has granted its patent application covering the company’s monoclona... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 09.02.2023 | RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non- Executive Directors | LONDON, UK, 9 February 2023 — RQ Bio is scaling up at speed, with the appointment of Non- Executive Directors, Dr W. Ripley (“Rip”) Ballou and Dr Jacques Cholat to its Board of Directors. Both new Non-Executive Directors have exte... |
| 01.02.2023 | LifeArc Ventures – strong performance in 2022 & sustained investment in innovation | LONDON, UK, 1 February 2023 — LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio. Clare Terlouw, Head of LifeArc Ventures, said: “Our tea... |
| 10.01.2023 | LifeArc portfolio company RQ Bio’s antibody enters clinical trials | LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD3152, has entered clinical trials – less than 12 months after discovery... |
Show more